These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 21871984)
1. Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations. Howard-McNatt M; Schroll RW; Hurt GJ; Levine EA Am J Surg; 2011 Sep; 202(3):298-302. PubMed ID: 21871984 [TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241 [TBL] [Abstract][Full Text] [Related]
4. Breast reconstruction in patients with personal and family history of breast cancer undergoing contralateral prophylactic mastectomy, a 10-year experience. Unukovych D; Sandelin K; Wickman M; Arver B; Johansson H; Brandberg Y; Liljegren A Acta Oncol; 2012 Sep; 51(7):934-41. PubMed ID: 22409595 [TBL] [Abstract][Full Text] [Related]
5. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA; J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327 [TBL] [Abstract][Full Text] [Related]
6. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation. Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW Breast J; 2004; 10(6):475-80. PubMed ID: 15569201 [TBL] [Abstract][Full Text] [Related]
7. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104 [TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
9. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL; N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993 [TBL] [Abstract][Full Text] [Related]
10. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy. Murphy RX; Adkinson JM; Namey T; Eid S; Bleznak A Ann Plast Surg; 2010 May; 64(5):684-7. PubMed ID: 20395792 [TBL] [Abstract][Full Text] [Related]
11. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209 [TBL] [Abstract][Full Text] [Related]
12. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction. Rueth NM; McMahon M; Arrington AK; Swenson K; Leach J; Tuttle TM Ann Surg Oncol; 2011 Sep; 18(9):2515-20. PubMed ID: 21424371 [TBL] [Abstract][Full Text] [Related]
13. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Arrington AK; Jarosek SL; Virnig BA; Habermann EB; Tuttle TM Ann Surg Oncol; 2009 Oct; 16(10):2697-704. PubMed ID: 19653045 [TBL] [Abstract][Full Text] [Related]
14. Preoperative genetic testing affects surgical decision making in breast cancer patients. Lokich E; Stuckey A; Raker C; Wilbur JS; Laprise J; Gass J Gynecol Oncol; 2014 Aug; 134(2):326-30. PubMed ID: 24910453 [TBL] [Abstract][Full Text] [Related]
15. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
16. [Surgical prevention of breast carcinoma in patients with hereditary risk]. Dražan L; Veselý J; Hýža P; Kubek T; Foretová L; Coufal O Klin Onkol; 2012; 25 Suppl():S78-83. PubMed ID: 22920212 [TBL] [Abstract][Full Text] [Related]
17. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Chung A; Huynh K; Lawrence C; Sim MS; Giuliano A Ann Surg Oncol; 2012 Aug; 19(8):2600-6. PubMed ID: 22396004 [TBL] [Abstract][Full Text] [Related]
18. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Fatouros M; Baltoyiannis G; Roukos DH Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. Meijers-Heijboer H; van Geel B; van Putten WL; Henzen-Logmans SC; Seynaeve C; Menke-Pluymers MB; Bartels CC; Verhoog LC; van den Ouweland AM; Niermeijer MF; Brekelmans CT; Klijn JG N Engl J Med; 2001 Jul; 345(3):159-64. PubMed ID: 11463009 [TBL] [Abstract][Full Text] [Related]
20. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Ardern-Jones A; Kenen R; Eeles R Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]